JP2023539113A5 - - Google Patents

Info

Publication number
JP2023539113A5
JP2023539113A5 JP2023512107A JP2023512107A JP2023539113A5 JP 2023539113 A5 JP2023539113 A5 JP 2023539113A5 JP 2023512107 A JP2023512107 A JP 2023512107A JP 2023512107 A JP2023512107 A JP 2023512107A JP 2023539113 A5 JP2023539113 A5 JP 2023539113A5
Authority
JP
Japan
Prior art keywords
deuterium
disorder
substituted
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539113A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/072898 external-priority patent/WO2022038171A1/en
Publication of JP2023539113A publication Critical patent/JP2023539113A/ja
Publication of JP2023539113A5 publication Critical patent/JP2023539113A5/ja
Priority to JP2026037834A priority Critical patent/JP2026120523A/ja
Pending legal-status Critical Current

Links

JP2023512107A 2020-08-18 2021-08-18 フェネチルアミン誘導体、組成物およびその使用方法 Pending JP2023539113A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026037834A JP2026120523A (ja) 2020-08-18 2026-03-10 フェネチルアミン誘導体、組成物およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063067303P 2020-08-18 2020-08-18
US63/067,303 2020-08-18
US202063131974P 2020-12-30 2020-12-30
US63/131,974 2020-12-30
PCT/EP2021/072898 WO2022038171A1 (en) 2020-08-18 2021-08-18 Phenethylamine derivatives, compositions, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026037834A Division JP2026120523A (ja) 2020-08-18 2026-03-10 フェネチルアミン誘導体、組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2023539113A JP2023539113A (ja) 2023-09-13
JP2023539113A5 true JP2023539113A5 (cg-RX-API-DMAC7.html) 2024-07-26

Family

ID=77564095

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023512107A Pending JP2023539113A (ja) 2020-08-18 2021-08-18 フェネチルアミン誘導体、組成物およびその使用方法
JP2023512063A Active JP7802769B2 (ja) 2020-08-18 2021-08-18 治療用フェネチルアミン組成物およびその使用方法
JP2025185299A Pending JP2026041715A (ja) 2020-08-18 2025-11-04 治療用フェネチルアミン組成物およびその使用方法
JP2026037834A Pending JP2026120523A (ja) 2020-08-18 2026-03-10 フェネチルアミン誘導体、組成物およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023512063A Active JP7802769B2 (ja) 2020-08-18 2021-08-18 治療用フェネチルアミン組成物およびその使用方法
JP2025185299A Pending JP2026041715A (ja) 2020-08-18 2025-11-04 治療用フェネチルアミン組成物およびその使用方法
JP2026037834A Pending JP2026120523A (ja) 2020-08-18 2026-03-10 フェネチルアミン誘導体、組成物およびその使用方法

Country Status (7)

Country Link
US (4) US12630504B2 (cg-RX-API-DMAC7.html)
EP (2) EP4200290A1 (cg-RX-API-DMAC7.html)
JP (4) JP2023539113A (cg-RX-API-DMAC7.html)
KR (3) KR20230053611A (cg-RX-API-DMAC7.html)
AU (2) AU2021327136B2 (cg-RX-API-DMAC7.html)
CA (2) CA3186357A1 (cg-RX-API-DMAC7.html)
WO (2) WO2022038170A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
US12465578B2 (en) 2021-09-25 2025-11-11 Alexander Shulgin Research Institute, Inc. Substituted alpha-ethyl phenylalkylamines
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
AU2023351134A1 (en) * 2022-09-26 2025-05-08 Alexander Shulgin Research Institute 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-aminium chloride
JP2026513655A (ja) * 2022-10-28 2026-04-30 サイビン アイアールエル リミテッド フェネチルアミン化合物、組成物、及び使用方法
AU2024303691A1 (en) * 2023-06-15 2026-01-08 Tactogen Inc New formulations for mental disorders or mental enhancement
WO2025228547A1 (en) 2024-05-01 2025-11-06 Cybin Irl Limited Processes for preparing phenethylamine compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
DE19859684A1 (de) 1998-12-23 2000-06-29 Bayer Ag Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
JP2002293764A (ja) * 2001-01-26 2002-10-09 Takeda Chem Ind Ltd アミノエタノール誘導体
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006079999A2 (en) 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
WO2008016677A2 (en) * 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
CA2682432C (en) 2007-03-30 2017-06-06 Duke University Device and method for delivery of a medicament
US20090318454A1 (en) 2008-03-24 2009-12-24 Weiner Carl P Novel antioxidants and methods of treatment
WO2016040822A1 (en) 2014-09-12 2016-03-17 Pinpoint Testing, Llc Ready-to-constitute analytical platforms for chemical analyses and quantification
CN107011313B (zh) 2016-01-27 2021-11-30 天士力医药集团股份有限公司 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用
US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
US11723894B2 (en) 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
CN112430187B (zh) 2019-08-07 2023-01-17 北京奇点势能科技有限公司 一种α,β-氘代胺类化合物、氘代药物及其制备方法
US11246860B2 (en) 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
EP4221682A2 (en) 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US20220267252A1 (en) 2021-02-24 2022-08-25 Mind Medicine, Inc. Mescaline derivatives with modified action
US20220323378A1 (en) 2021-04-03 2022-10-13 Shawn Joseph Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity
WO2022221942A1 (en) 2021-04-19 2022-10-27 Betterlife Pharma Inc. Prevention of drug diversion
WO2022225884A1 (en) 2021-04-22 2022-10-27 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psychedelic compounds and uses thereof
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ, インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
US20240335401A1 (en) 2021-06-23 2024-10-10 Synaptive Therapeutics Llc Substituted phenethylamine for treating inflammation and psychological disorders
WO2023283386A2 (en) 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
AU2022311812A1 (en) 2021-07-14 2023-08-24 Altrartis Therapeutics Inc. Novel short-acting psychoactive compounds of the mdma class
EP4387952A1 (en) 2021-08-20 2024-06-26 Terran Biosciences Inc. Deuterated analogs and derivatives of 4-bromo-2,5-dimethoxyphenethylamine and uses thereof
AU2022342266B2 (en) 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies
US12465578B2 (en) 2021-09-25 2025-11-11 Alexander Shulgin Research Institute, Inc. Substituted alpha-ethyl phenylalkylamines
US20250236589A1 (en) 2022-02-15 2025-07-24 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
AU2023222126A1 (en) 2022-02-15 2024-08-08 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
US20250205198A1 (en) 2022-03-31 2025-06-26 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
AU2023242469A1 (en) 2022-03-31 2024-09-05 Cybin Irl Limited Combination of nitrous oxide and 5-ht2a receptor agonists
JP2026513655A (ja) 2022-10-28 2026-04-30 サイビン アイアールエル リミテッド フェネチルアミン化合物、組成物、及び使用方法

Similar Documents

Publication Publication Date Title
JP2023540017A5 (cg-RX-API-DMAC7.html)
JP2025505745A5 (cg-RX-API-DMAC7.html)
JP2023526856A5 (cg-RX-API-DMAC7.html)
JP2025506504A5 (cg-RX-API-DMAC7.html)
JP2022545633A5 (cg-RX-API-DMAC7.html)
JP2024522065A5 (cg-RX-API-DMAC7.html)
JP2023551058A5 (cg-RX-API-DMAC7.html)
JP2021522262A5 (cg-RX-API-DMAC7.html)
JP2021523200A5 (cg-RX-API-DMAC7.html)
JP2004511556A5 (cg-RX-API-DMAC7.html)
JP2005516067A5 (cg-RX-API-DMAC7.html)
CA2470476A1 (en) Pyrrolidine and piperidine derivates as nk1 antagonists
CA2758474A1 (en) Novel p2x7r antagonists and their use
JP2023533203A5 (cg-RX-API-DMAC7.html)
JP2025509697A5 (cg-RX-API-DMAC7.html)
JP2023518044A5 (cg-RX-API-DMAC7.html)
JP2016526023A5 (cg-RX-API-DMAC7.html)
JP2023509944A5 (cg-RX-API-DMAC7.html)
JP2024534111A5 (cg-RX-API-DMAC7.html)
JP2009500425A5 (cg-RX-API-DMAC7.html)
JP2018503647A5 (cg-RX-API-DMAC7.html)
JP2025111616A5 (cg-RX-API-DMAC7.html)
JP2019214626A5 (cg-RX-API-DMAC7.html)
JP2019524752A5 (cg-RX-API-DMAC7.html)
JP2005530809A (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用